Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors
Condition(s) studied
Investigational drug(s) / intervention(s)
Neoantigen mRNA Vaccine: Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.
Study summary
The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate mRNA sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the mRNA vaccine for immunotherapy of human cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the mRNA vaccine immunotherapy on human cancers will firstly be evaluated.
Eligibility
Primary outcome measure(s)
- Number of Patients with Dose Limiting Toxicity — Six months
A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the vaccine, which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Second Affiliated Hospital of Guangzhou Medical University | Guangzhou | Guangdong | Recruiting |
More Second Affiliated Hospital of Guangzhou Medical University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06195384 on ClinicalTrials.gov ↗ ← All trials in China